Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Males aged 18 years or older
- People diagnosed with a specific type of prostate cancer called prostate adenocarcinoma
- People whose PSA level (a prostate cancer marker measured in blood) is 2.0 ng/mL or higher at the screening visit
- People whose PSA levels have risen — with or without changes visible on scans — after being on the medications abiraterone and prednisone for at least 12 weeks
- People who are currently on hormone-suppressing injections (GnRH analogues) or who have had surgical removal of the testicles
- People with a life expectancy of at least 6 months
- People who are able to swallow tablet medications
- People willing to avoid alcohol during treatment and for 14 days after taking a study medication called metronidazole
- People willing and able to collect urine and stool samples as required by the study
Who may not be able to join:
- People with an active infection or other health condition that would make a steroid medication called dexamethasone unsafe to use
- People who require ongoing higher doses of steroid medications for a chronic health condition
- People whose prostate cancer has a specific aggressive cell type called small cell carcinoma
- People who have, or are at immediate risk of, spinal cord compression based on clinical assessment or MRI scans
- People with severe chronic liver disease (classified as Child-Pugh class C cirrhosis — confirm with trial site)
- People with certain abnormal liver blood test results above specified thresholds (confirm exact values with trial site)
- People with a heart rhythm condition involving a prolonged QTc interval, either inherited or measured above 500 milliseconds on a heart tracing
- People with a history of problems affecting the pituitary gland or adrenal glands
- People with poorly controlled diabetes (HbA1c above 10%) or whose insulin doses have been increased in the past 4 weeks due to poor blood sugar control
- People who have received another experimental treatment or had a major surgical procedure (not including surgical removal of the testicles) within 30 days before the study begins, or who are currently in another experimental drug study
- People with certain serious illnesses, including uncontrolled major infections, Crohn's disease, ulcerative colitis, toxic megacolon, small bowel blockage, or a known allergy to any of the study medications
- People who have taken antibiotic medications within 30 days before starting the study treatment
- People who have any other condition or situation that the trial doctor believes could put them at risk or interfere with their participation
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Catherine Handy Marshall, M.D., Johns Hopkins University
Phone: 410-502-7635
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with PSA30 response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.